Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Pipeline Review, H2 2018’, provides in depth analysis on Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Oncology, Infectious Disease, Metabolic Disorders and Undisclosed under development targeting Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)

- The report reviews Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects

- The report assesses Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Astellas Pharma Inc

Celgene Corp

CompleGen Inc

Takeda Pharmaceutical Co Ltd

AbbVie Inc

Astellas Pharma Inc

Celgene Corp

CompleGen Inc

Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Overview

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Companies Involved in Therapeutics Development

AbbVie Inc

Astellas Pharma Inc

Celgene Corp

CompleGen Inc

Takeda Pharmaceutical Co Ltd

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Drug Profiles

AS-2521780 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-90005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CGX-0471 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CGX-1079 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit KDM1A and PRKCQ for Metastatic Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

englerin A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PKC-Theta for Unspecified Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Ewing Sarcoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PRKCQ for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Protein Kinase C Theta for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Dormant Products

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Discontinued Products

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Product Development Milestones

Featured News & Press Releases

Feb 11, 2016: UC launches new cancer therapeutic company

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number ...

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by AbbVie Inc, H2 2018

Pipeline by Astellas Pharma Inc, H2 2018

Pipeline by Celgene Corp, H2 2018

Pipeline by CompleGen Inc, H2 2018

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Dormant Projects, H2 2018

Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number ...

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports